75
Participants
Start Date
January 11, 2022
Primary Completion Date
April 29, 2024
Study Completion Date
April 30, 2026
Plozasiran
ARO-APOC3 injection
Placebo
sterile normal saline (0.9% NaCl)
NZCR OPCO Ltd, Auckland
Middlemore Clinical Trials, Auckland
Royal Prince Alfred Hospital, Camperdown
Royal North Shore Hospital, St Leonards
Universitair Ziekenhuis Antwerpen (UZA), Edegem
Universitaire Ziekenhuizen Leuven, Leuven
Baker Heart and Diabetes Institute, Melbourne
Austin Health, Melbourne
Instituto Modelo de Gastroenterologia, Formosa
Centre Hospitalier Universitaire (CHU) de Liege, Liège
Universitaetsklinikum Leipzig, Leipzig
Linear Clinical Research Ltd, Nedlands
Universitaetsklinikum Jena, Jena
New Zealand Clinical Research, Christchurch
Medizinische Universitaet Graz, Graz
University Hospital Ghent, Ghent
University Hospital Center Zagreb -Rebro, Department for Metabolic Diseases, Zagreb
New York University Langone Medical Center, New York
Icahn School of Medicine at Mt. Sinai, New York
Clinical Center of Serbia, Institute of Endocrinology, Diabetes and Metabolic Diseases, Belgrade
Centro Especializado en Diabetes Obesidad y Prevención de entermedades Cardiovasculares (CEDOPEC), Mexico City
AP-HM-Hopital de La Conception, Marseille
National Institute of Medical Sciences and Nutrition - Salvador Zubiran (INCMNSZ), Tlalpan
Hospital Abente y Lago, A Coruña
Hospital Clinico Universitario de Santiago, Santiago de Compostela
Clinical Centre Nis, Niš
Complejo Hospitalario Universitario de Granada - Hospital Universitario Virgen de las Nieves, Granada
Centennial Medical Group, Elkridge
York Clinical Research, LLC, Norfolk
Hospital General Universitario Gregorio Maranon, Madrid
Herman Clinical Research, LLC, Suwanee
Excel Medical Clinical Trials, LLC, Boca Raton
Ege University Hospital Department Of Infectious Diseases, Izmir
Erciyes University Faculty of Medicine, Melikgazi
Ascension St. Vincent Cardiovascular Research Institute, Indianapolis
Chonnam National University Hospital, Gwangju
Instituto de Diabetes Obesidad y Nutrición S.C., Cuernavaca
Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research, St Louis
AP-HP Hopital Pitie-Salpetriere, Paris
Texas Diabetes and Endocrinology, Austin
National University Hospital, Singapore
Hadassah Medical Center Ein Karem, Jerusalem
Instituto Medico DAMIC, Córdoba
Robarts Research Institute, London
Toronto General Hospital, Toronto
Ecogene-21, Chicoutimi
Institute de Recherches Cliniques de Montreal, Montreal
Clinique des Maladies Lipidiques de Quebec Inc., Québec
University Hospital Galway, Galway
Chiba University Hospital, Chiba
Kanazawa University Hospital, Ishikawa
Rinku General Medical Center, Osaka
Jichi Medical University Hospital, Tochigi
Tokyo University Hospital, Tokyo
Nippon Medical School Hospital, Tokyo
Sultan Qaboos University Hospital, Muscat
Instytut Centrum Zdrowia Matki Polki, Lodz
Seoul National University Hospital, Seoul
Lead Sponsor
Arrowhead Pharmaceuticals
INDUSTRY